Navigation Links
Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information

- PAH Pathways(TM) Program offers Patient Support and Financial Assistance


SOUTH SAN FRANCISCO, Calif., Dec. 18 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc. today announced results of a recent Harris Interactive(R) survey, showing that an overwhelming majority of Tracleer patients enrolled in Sure Steps find the patient support program valuable, and feel that their knowledge of pulmonary arterial hypertension (PAH) and Tracleer have improved due to the program. The Sure Steps program, part of Actelion's PAH Pathways(TM) service and support program, is a support and education program available to all PAH patients on Actelion's PAH products, Tracleer and Ventavis(R) (iloprost) Inhalation Solution.
Key findings from the survey of patients enrolled in Sure Steps show that:

-- Nine in ten (89 percent) enrolled patients are satisfied with the


-- Almost all (97 percent) would recommend the program to other PAH

patients on Tracleer;

-- Six out of seven (85 percent) enrolled patients are more comfortable

discussing their PAH therapy with their physicians because of the

program; and

-- 92 percent feel better informed about Tracleer as a result of

information provided in the program.

The survey was conducted by Harris Interactive on behalf of Actelion between August 7 and August 21, 2007. It included more than 600 patients currently enrolled in Sure Steps, 256 of whom who had been on Tracleer for less than one year, and 354 patients who had been on Tracleer for more than a year. All patients were 18 year of age or older, diagnosed with PAH, currently taking Tracleer, and had been enrolled in the Sure Steps program for at least two months.

"When patients are first diagnosed with PAH and begin treatment, they are often overwhelmed by their diagnosis and have many questions about treatment," said Craig Hopkinson, MD, Vice President of U.S. Medical Affairs at Actelion. "Sure Steps is a unique program that provides meaningful assistance to these patients and resources to learn more about their condition beginning immediately after they start their treatment."

About PAH Pathways and Sure Steps

PAH Pathways(TM) is Actelion's service and support program for physicians and their patients currently on either of Actelion's PAH medications, including Tracleer and Ventavis. The program is designed to provide access to therapy, ensuring patients receive therapy as quickly as possible, and comprehensive financial and reimbursement support to eligible patients. In addition, PAH Pathways recently introduced a program that offers eligible patients starting on Tracleer with their first month of therapy at no cost to the patient.

Sure Steps, an important part of the PAH Pathways offering, is a support and education program for patients with PAH who are taking one of Actelion's PAH medications. The program provides ongoing information and personal assistance to help these patients manage their condition. Patients enrolled in Sure Steps receive direct access to a nurse counselor who can help answer questions regarding PAH or Tracleer, ongoing informational newsletters, and important tools to help them cope with PAH. Over 3,500 patients have enrolled in Sure Steps to date. Eligible patients can enroll by calling 1-866-682-7873. Sure Steps is also available to patients who are taking Ventavis for the treatment PAH.

About Tracleer(R) in Pulmonary Arterial Hypertension (PAH)

Tracleer(R) (bosentan), the first oral dual endothelin receptor antagonist, is approved for the treatment of pulmonary arterial hypertension (PAH) World Health Organization (WHO) Functional Class III or IV and made available by Actelion Ltd. subsidiaries in the United States, the European Union, Japan, Australia, Canada, Switzerland and other markets worldwide.

Tracleer requires attention to two significant safety concerns: potential for serious liver injury (including rare cases of liver failure and unexplained hepatic cirrhosis in a setting of close monitoring) and high potential for major birth defects. Liver monitoring of all patients is essential prior to initiation of treatment and monthly thereafter. Pregnancy must be excluded and prevented by two forms of birth control; monthly pregnancy tests should be obtained. Because of these risks, Tracleer is only supplied through a controlled distribution system, the Tracleer Access Program (T.A.P.(R))

About Ventavis(R)

Ventavis(R) (iloprost) is an inhaled formulation of iloprost, a synthetic compound that is structurally similar to prostacyclins -- naturally occurring molecules that cause blood vessels to dilate. Ventavis is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with New York Heart Association (NYHA) Functional Class III or IV. In controlled trials, Ventavis improved a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration.

In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. Ventavis should not be initiated in patients with systolic blood pressure less than 85 mm Hg. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension.

About Actelion Pharmaceuticals

Actelion Pharmaceuticals has pioneered research and development in the pulmonary arterial hypertension (PAH) disease area. More than 40,000 PAH patients have been prescribed Actelion's product Tracleer, an orally available dual endothelin receptor antagonist for patients with PAH with World Health Organization (WHO) Functional Class III or IV in the U.S., and Functional Class III in Europe. Tracleer was approved in 2001 as the first oral treatment for PAH, and is currently approved in the U.S., the European Union, and other markets worldwide. In January 2007, Actelion acquired CoTherix, Inc., whose product Ventavis is approved and marketed in the United States for the treatment of PAH patients with New York Heart Association (NYHA) Functional Class III or IV.

SOURCE Actelion Pharmaceuticals US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition
2. International Survey Shows People Over Forty Ignore Risk of Blindness
3. 2007 Global Survey Identifies Characteristics of Supply Chain Leaders
4. Survey Sees Mass. CEOs as Bullish on Own Businesses
5. Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey
6. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
7. National Survey Shows Most Women Are Not Satisfied With Their Progesterone Treatment
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015 Spherix Incorporated (Nasdaq: ... to the fostering and monetization of intellectual property, ... prospective initiatives designed to create shareholder value. ... of Spherix. "Based on published reports, the total ... $50 billion and Spherix will seek to secure ...
(Date:11/30/2015)... , Nov. 30, 2015  HUYA Bioscience International, ... China,s pharmaceutical innovations, today announced it has ... Development Fund (KDDF) to foster collaboration between KDDF and ... and commercialization of healthcare products for the global market. ... an important source of new innovative preclinical and clinical ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announced tighter software integration with MarkLogic, the Enterprise NoSQL database platform provider, ... to drive change. , Smartlogic’s Content Intelligence capabilities provide a robust set ...
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is one ... biomarkers market with pharmaceutical companies and diagnostic ... diagnostic tests. . ... Complete report on global cancer biomarkers market ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 Paris ... 2015.   --> Paris from 17 ... DERMALOG, the biometrics innovation leader, has invented the first ... fingerprints on the same scanning surface. Until now two different ... Now one scanner can capture both on the same ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
Breaking Biology News(10 mins):